Lapatinib Ratiopharm (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of both EGFR (ErbB1) and HER2 (ErbB2). By preventing autophosphorylation, it disrupts downstream signaling pathways like PI3K/AKT and MAPK, which are essential for tumor cell growth, survival, and angiogenesis.

The dose of Lapatinib Ratiopharm is determined by the prescribing physician based on clinical guidelines, disease stage, and individual patient factors. Patients should follow the exact regimen provided by their oncologist and not adjust the dose on their own.

Safety of Lapatinib in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal or infant risk. Women of child‑bearing potential should use effective contraception and discuss any plans for pregnancy with their healthcare provider.

To order Lapatinib Ratiopharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lapatinib is a small‑molecule tyrosine kinase inhibitor, whereas the main alternative, trastuzumab, is a monoclonal antibody targeting the extracellular HER2 domain. Lapatinib can be taken orally and may be combined with trastuzumab for dual HER2 blockade, while trastuzumab is administered intravenously and has a different safety profile, especially regarding cardiac toxicity.

Lapatinib Ratiopharm tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

Lapatinib is administered orally as a tablet, usually taken once daily with or without food, according to the prescribing physician’s instructions. Patients should swallow the tablet whole with water and follow any specific timing recommendations related to other concomitant medications.

Serious risks include hepatotoxicity (elevated liver enzymes or hepatitis), cardiac dysfunction such as reduced left‑ventricular ejection fraction, interstitial lung disease, and severe skin reactions like Stevens‑Johnson syndrome. Patients should report any signs of liver injury, shortness of breath, chest pain, or severe rash to their healthcare provider promptly.

Lapatinib should not be used by patients with known hypersensitivity to the drug or any of its excipients, those with severe hepatic impairment (Child‑Pugh C), or individuals with uncontrolled cardiac disease. Caution is also advised for patients taking medications that significantly affect CYP3A4 metabolism.